Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed

6 November 2025

Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) reported third‑quarter 2025 results this morning (Nov. 6), highlighting sequential revenue growth, materially higher gross margins, and steady commercial momentum for its tumor‑infiltrating lymphocyte (TIL) therapy Amtagvi. Management also reaffirmed full‑year revenue guidance and flagged pipeline milestones led by encouraging lung‑cancer data for lifileucel. ^[1]

Q3 revenue ~$68M, up ~13% QoQ; gross margin 43%. The company cited improved execution and early benefits of cost optimization. Full‑year 2025 revenue guidance remains $250–$300M in Amtagvi’s first full calendar year on the market. ^[2]
Bottom line: Net loss of $91.3M (‑$0.25 per share). Revenue of $67.5M missed consensus, while EPS beat some estimates, according to Associated Press/Zacks summaries. ^[3]
Regulatory & pipeline: Interim IOV‑LUN‑202 data in nonsquamous NSCLC show an ~26% ORR with median duration of response not reached (>25 months), supporting plans to pursue regulatory pathways; more data are expected in 2026. ^[4]
Operations & access: >80 U.S. authorized treatment centers now active; distribution broadened via a specialty‑pharmacy agreement with InspiroGene by McKesson; average manufacturing turnaround ~32 days. ^[5]
Liquidity: Cash, equivalents, investments, and restricted cash ~$307M at Sept. 30; runway expected into Q2 2027 after recent cost actions. ^[6]
Compliance note: Iovance furnished its results and press release via an SEC Form 8‑K this morning. ^[7]

What Iovance announced (Nov. 6, 2025)

Revenue, margin, and guidance. Total product revenue grew to ~$68M in Q3 (Amtagvi ~$58M; Proleukin ~$10M). Gross margin expanded to 43% on improved execution and early cost‑savings. Management reaffirmed $250–$300M in 2025 revenue. ^[8]

Earnings snapshot. An AP/Automated Insights brief noted a net loss of $91.3M or ‑$0.25 per share on $67.5M in revenue, with EPS topping some forecasts but sales below Street expectations. ^[9]

Filing & webcast. The company filed an 8‑K with the press release and scheduled a conference call and webcast at 8:30 a.m. ET to review results and provide updates. ^[10]

Investor materials. Iovance also posted a fresh corporate presentation dated today, aligning with the Q3 update. ^[11]

Commercial execution: where growth is coming from

Treatment‑center footprint. Iovance says >80 U.S. authorized treatment centers (ATCs) are active across nearly 40 states, placing ~95% of eligible patients within a ~two‑hour drive. Expansion into community centers is expected to support earlier treatment and demand. ^[12]
Patient access & logistics. A new specialty‑pharmacy agreement with InspiroGene by McKesson is intended to broaden access. Meanwhile, manufacturing turnaround averages ~32 days from inbound tumor sample to shipment back to ATCs, with further operational initiatives underway. ^[13]
Global expansion.Health Canada approved Amtagvi in August 2025; Iovance anticipates potential approvals in the U.K. and Australia in 1H26 and in Switzerland in 2027, and is finalizing an EMA strategy. ^[14]

Pipeline update: lifileucel beyond melanoma

NSCLC (IOV‑LUN‑202). Interim Phase 2 monotherapy data in previously treated nonsquamous NSCLC reported an ~26% objective response rate with median DOR not reached after >25 months. The design has positive FDA feedback, and Iovance expects enrollment completion in 2026, targeting a supplemental BLA and a potential 2027 launch if successful. ^[15]
Broader development. Early readouts for endometrial cancer (IOV‑END‑201) are planned for early 2026; the TILVANCE‑301 combo trial (lifileucel + pembrolizumab) continues in frontline melanoma; next‑gen programs IOV‑4001 (PD‑1–inactivated TIL), IOV‑3001 (next‑gen IL‑2), and IOV‑5001 (inducible tethered IL‑12 TIL) are slated for updates through 2026. ^[16]

By the numbers (Q3 2025)

Revenue: ~$68M (Amtagvi ~$58M; Proleukin ~$10M) — up ~13% QoQ. ^[17]
Gross margin:43% (improved execution/cost optimization). ^[18]
Net loss / EPS:‑$91.3M / ‑$0.25; revenue $67.5M vs. lower‑Street consensus in AP brief. ^[19]
Cash & investments:~$307M (runway into Q2 2027). ^[20]

Market reaction (intraday)

As of publication time, IOVA shares were trading around $2.16 intraday, with the session range between $1.76–$2.41 (time stamp ~14:42 UTC). See live chart above.

What to watch next

Commercial ramp cadence. Watch activation and throughput at community ATCs, the InspiroGene distribution channel, and any additional real‑world data disclosures that might influence adoption curves. ^[21]
Manufacturing consolidation. The plan to centralize manufacturing at the Iovance Cell Therapy Center (iCTC) in early 2026 could be a margin lever; execution will matter. ^[22]
Ex‑U.S. milestones. Decisions or filings in the U.K., Australia (1H26), and Switzerland (2027), plus progress on the EMA path. ^[23]
NSCLC readouts. Additional IOV‑LUN‑202 data (planned 2026) and regulatory interactions that may set the pace toward a 2027 launch. ^[24]

Source notes (Nov. 6, 2025)

Company press release summarizing Q3 results, operations, and pipeline; webcast details and guidance. ^[25]
SEC Form 8‑K furnishing the Q3 press release. ^[26]
AP/Automated Insights earnings snapshot syndicated via Hearst (Times Union). ^[27]
Quiver Quantitative note on consensus beats/misses. ^[28]
Corporate presentation posted today (MarketScreener/PublicNow). ^[29]
Nov. 3 Iovance press release and independent coverage on IOV‑LUN‑202 interim data in NSCLC. ^[30]

Editor’s note: This article is for informational purposes only and does not constitute investment advice.

Iovance Biotherapeutics (IOVA) 🧬💉Strong Revenue, Extremely Undervalued! #millionaire #healthcare

Watch this video on YouTube.

References

Tags:

Mateusz Kaczmarek Latest posts

A technology and finance expert writing for TS2.tech. He analyzes developments in satellites, telecommunications, and artificial intelligence, with a focus on their impact on global markets. Author of industry reports and market commentary, often cited in tech and business media. Passionate about innovation and the digital economy.

View all

Outflows Detected in QUAL ETF Prompt Market Attention; Top Holdings TJX, KLAC, ADBE Under Pressure
November 6, 2025, 2:44 PM EST. Week-over-week, the iShares MSCI USA Quality Factor ETF (QUAL) shows an approximate $458.9 million outflow, a 0.9% decline in shares to 267,950,000. Among QUAL's largest components, TJX is off about 0.7%, KLAC about 1.1%, and ADBE around 2% lower. The ETF's 52-week range spans $148.34 to $199.97, with the latest trade at $194.22. The chart highlights a check against the 200-day moving average. Note that ETF flows reflect creation/destruction of units, potentially affecting underlying holdings. For the full holdings list, see the QUAL Holdings page.
VTEB ETF Inflow Alert: ~$200.3M Inflow, 0.6% WoW Increase in Outstanding Units
November 6, 2025, 2:42 PM EST. Vanguard Tax-Exempt Bond ETF (VTEB) saw an approximate $200.3 million inflow, a 0.6% week-over-week increase in outstanding shares/units (from 645,741,219 to 649,735,696) per ETF Channel. The accompanying chart highlights VTEB's one-year performance against its 200-day moving average, with a 52-week range of $47.14 to $51.15 and a last traded price of $49.96. Inflows require the ETF to purchase more underlying holdings, while unit creation or destruction can influence its components. Ongoing demand signals can indicate investor preference for tax-exempt bond exposure, suggesting watching for further inflow activity and any shifts in the portfolio as new units are issued.
VGSH Inflows Hit $173.9M as Unit Count Rises 1.3%
November 6, 2025, 2:40 PM EST. The Vanguard Short-Term Treasury ETF VGSH posted a roughly $173.9 million inflow, a 1.3% week-over-week gain in outstanding units (from 229,252,650 to 232,202,650). A chart compares its one-year price performance to the 200-day moving average. The 52-week range runs from $58.84 to $61.57, with a last trade around $58.91. ETFs trade like stocks, but investors buy and sell units that can be created or destroyed to meet demand. Weekly flow monitoring flags notable inflows or outflows; creation of new units requires buying underlying holdings, while destruction involves selling them. Click to see the other 9 ETFs with notable inflows.
VMBS Sees $212M Outflow Week Over Week; Shares Fall About 1.1%
November 6, 2025, 2:38 PM EST. VMBS, the Vanguard Mortgage-Backed Securities ETF, shows a notable week-over-week outflow of about $212.1 million, reducing shares outstanding by roughly 1.1% to 393,117,358 from 397,617,309. The current quote sits near $47.23, within a 52-week range of $42.06-$47.31. The chart also highlights its 200-day moving average as a technical gauge. ETF unit creation/destruction means inflows or outflows can influence underlying holdings; investors should watch whether the outflow accelerates or stabilizes and how it may affect exposure to the mortgage-backed securities basket.
JPMorgan urges investors to buy the dips as the stock bull market rages on
November 6, 2025, 2:36 PM EST. JPMorgan strategists argue that investors can view dips as opportunities in a robust bull market. They point to resilient earnings, ample liquidity, and a continued appetite for risk as reasons to buy on pullbacks rather than panic. While the stance favors select, high-quality names and disciplined position sizing, it also warns that macro shocks or a regime shift in policy could alter the balance. The note emphasizes diversification, risk controls, and a clear plan to ride incremental gains while avoiding overexposure to crowded trades. In short, dips may be optimal entry points, but success depends on patience, risk management, and focus on fundamentals in a bull market.

Iovance Biotherapeutics (IOVA) Q3 2025: Revenue Climbs ~13% to ~$68M; Gross Margin Hits 43%, Guidance Reaffirmed — November 6, 2025

What Iovance announced (Nov. 6, 2025)

Commercial execution: where growth is coming from

Pipeline update: lifileucel beyond melanoma

By the numbers (Q3 2025)

Market reaction (intraday)